Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

Valentina Mazza,1 Federico Cappuzzo1,2 1Department of Oncology-Hematology, 2Department of Medical Oncology, AUSL Romagna, Ravenna, Italy Abstract: The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-mutant non-small cell lung cancer (NSCLC), a p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mazza V, Cappuzzo F
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Dove Medical Press 2017-07-01
Colecção:	The Application of Clinical Genetics
Assuntos:	NSCLC (non-small-cell lung cancer) EGFR (Epidermal Growth Factor Receptor) TKI (Tirosine-Kinase Inhibitors) acquired resistance T790M osimertinib.
Acesso em linha:	https://www.dovepress.com/treating-egfr-mutation-resistance-in-non-small-cell-lung-cancer---role-peer-reviewed-article-TACG
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!